Opko Health Inc. (NASDAQ:OPK) was down 14.8% during trading on Friday . The stock traded as low as $3.77 and last traded at $3.90. Approximately 28,303,523 shares traded hands during mid-day trading, an increase of 410% from the average daily volume of 5,547,721 shares. The stock had previously closed at $4.58.

Several equities research analysts have recently commented on OPK shares. BidaskClub raised Opko Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 10th. ValuEngine downgraded Opko Health from a “sell” rating to a “strong sell” rating in a report on Friday, July 6th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, August 7th. Finally, Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a research note on Friday, May 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Opko Health currently has an average rating of “Hold” and an average price target of $10.95.

The company has a quick ratio of 0.90, a current ratio of 1.05 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -14.41 and a beta of 2.09.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The business had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million. equities analysts forecast that Opko Health Inc. will post -0.23 earnings per share for the current year.

In other Opko Health news, CEO Phillip Md Et Al Frost purchased 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 21st. The shares were acquired at an average price of $4.54 per share, for a total transaction of $136,200.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $13,933,037.54. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders purchased 334,519 shares of company stock worth $1,760,069. 42.74% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the business. Northern Trust Corp increased its position in Opko Health by 4.0% during the 1st quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock worth $5,549,000 after buying an additional 66,562 shares during the period. OMERS ADMINISTRATION Corp bought a new position in shares of Opko Health in the second quarter worth $557,000. Boulegeris Investments Inc. increased its position in shares of Opko Health by 11.4% in the second quarter. Boulegeris Investments Inc. now owns 273,680 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 28,075 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Opko Health by 22.0% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 210,782 shares of the biotechnology company’s stock worth $991,000 after purchasing an additional 38,057 shares during the period. Finally, ING Groep NV bought a new position in shares of Opko Health in the second quarter worth $1,575,000. Hedge funds and other institutional investors own 24.79% of the company’s stock.

About Opko Health (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Article: Using the New Google Finance Tool

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.